Tuesday 27 June 2017 | The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares
Okay I do not own these shares personally. I case anyone is thinking of going for me in a libel case I own nothing but FIML, owned by my family trusts, has built from scratch a fairly sizeable portfolio of 18 stocks. For what it is worth here they are in descending order of current value.
On 25 April this year Optibiotix (OPTI) announced it had delivered a small sale of 100,000 units of its LPDL capsule to Germany's HLH BioPharma Vertriebs GmbH. That must have gone well as we are today told that Optibiotix has signed a three year deal that grants HLH a non-exclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LPLDL® strain.
OptiBiotix Health (OPTI) has announced what it terms the "successful" launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry. Yadda, yadda, yadda. Companies always say launches are successful. More jam tomorrow. So what. Etc. But no read on... We have underlined a few key words for you.
Shares in Optibiotix (OPTI) hit 60.5p mid at one point Wednesday but closed at 61p-63p. Having retipped this as a buy in the low seventies and at up to 80p we have received a number of emails saying "should we sell?" Some were citing savants on the LSE Bulletin Board who make dire predictions and others were asking what is wrong?
Morning Tom, people on the BB speculating you have sold your OPTI holding, can you confirm please?Thank you. That was one of the emails that I received this morning. The short answer is "its bollocks" but perhaps this merits a longer answer.
The A-Grade A'holes at Walbrook PR who charge Optibiotix (OPTI) thousands of quid a month for "news management" probably thought putting out two announcements on one day was part of a clever strategy. Whatever. If Optibiotix wants to save a few quid we have a suggestion....
In this video from the storming success that was the 2017 UK Investor Show, in the 'Dragon's Den' companies have a 60 second pitch to Gary Newman, Tom Winnifrith and Steve Moore for three £1,000 investments. This third round features Optibiotix (OPTI), Metal Tiger (MTR), Saffron Energy (SRON), Collagen Solutions (COS) and Wishbone Gold (WSBN).
OptiBiotix (OPTI) skin health-focused subsidiary, SkinBioTherapeutics, has successfully listed its shares on AIM. Good news as OptiBiotix still has a near 42% stake…
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.
If Optibiotix (OPTI) said that 2 +2 =4 then some folks would start banging on about how that means it cant equal three. There is no pleasing them. Thus after the cracking deal with Sacco announced earlier this week all some folks wanted to talk about was P&G.
Oh ye of little faith! Ye who panicked that Optibiotix (OPTI) has not publicly announced that the big name party in the last deal was Tata. Fear not it will and there will be exciting news on that soon. Ye who thought there were no more deals. You were wrong and that is why we have been urging you to buy the shares at up to 80p again and again. The shares are now 71p-74p.
An early contender for the most idiotic email of the day has just arrived. It compared an RNS out this morning from Optibiotix (OPTI) about launching new products and pushing existing ones to the sort of RNS that the recently suspended fraud Cloudtag (CTAG) used to issue. It is hard to know what to say in the face of such stupidity. There is a clear difference.
Critics of Obtibiotix (OPTI) reckon that it is all jam tomorrow and it needs to announce big name deals which see real rollout of its products and commercialisation. Well how would a deal with Boots for its Slimbiome weight-loss drinks and snack bars do for starters?
Optibiotix (OPTI) held an EGM of warrant holders earlier this week to vote on extending the date at which we must exercise out to 2022 from er...next week. There are really very few warrant holders left.
After languishing unloved for a while in the low sixties, shares in Optibiotix (OPTI) are really steaming ahead and are now 78p to buy. We hope you bought in the low sixties as we repeatedly urged. If not it is not too late. The shares are a buy at up to 80p and I expect to be advising you to sell at WELL OVER 100p by Easter. So what has happened?
There are some announcements that an AIM listed company has to make as they are material but in terms of excitement we are talking paint dry. So you just clear the decks and announce them and when all the news is out you - hopefully - have something to announce which will get folks interested. And so it is with Optibiotix (OPTI).
We cannot hide our disappointment that we go into Christmas with shares in Optibiotix (OPTI) trading at just 61-63p. They really should be far higher and we do expect an exciting re-rate in Q1 2017. We had expected it earlier but were wrong. We won't be this time!
On 29 November Optibiotix (OPTI) stated: "OptiBiotix reports that it has reached late stage commercial discussions with six commercial partners across its technology and product platforms.". The knockers said "jam tomorrow won't happen". This week the first of the six deals was announced and it is massive. More will follow as Adam Reynolds made clear yesterday exclusively HERE. The news is:
Earlier Adam and I chatted about Concepta (CPT). In this podcast we cover Optibiotix (OPTI) and Premaitha (NIPT).
We Optibiotix (OPTI) shareholders have been feeling a bit under the cosh of late as the shares weakened on a lack of news. It was just ennui among those of an impatient disposition but still it was annoying. This week's trading statement should reassure the doubters.
OptiBiotix Health (OPTI) has served up an update which is good but not the sort of fireworks investors were hoping for. As a result the shares closed at 61.5p-63p on the day which is, to say the least, disappointing. They are now 63p-66p which is better but still both disappointing and far too low.
Optibiotix (OPTI) has announced the appointment of Martin Hunt as Chairman and Director of its majority owned subsidiary SkinBiotix Limited. Why does this matter? Because this unit will be spun off with a separate AIM listing well before Christmas. This is one of the last box ticking to do before formal confirmation of the process.
We have been asked a few questions about Optibiotix (OPTI), none wildly important and so let's wrap them up into one article, in Q&A format.
The good news is that a 1.5 million share overhang in Optibiotix (OPTI) has now been cleared. So the shares should soar on good news. The bad news is that we have to wait a bit longer for that good news... Instead we get an RNS that was never going to set the share price on fire. Optibiotix has announced the results of a survey of customers of its GoFigure slimming shakes and bars. 30 lard buckets took part in the survey.
Results from the half calendar year from Optibiotix (OPTI) were very pleasing indeed but not orgasmic and that is why the shares are a tad weaker at 69p-72p. They are cheap but punters need to see more. They will not have to wait too long.
I have received a number of emails and texts asking if I am worried that shares in Optibiotix (OPTI) are 67-69p having fallen back of late. No I am not but to stem the flow of questions...
Optibiotix (OPTI) has announced that its GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15 billion turnover in 2015) American supermarket chain exclusively featuring healthy foods. That sounds big but in fact it means being on the shelves in just eight stores although Optibiotix says there are " opportunities for further expansion".
Okay, okay we did notice! In response to several reader emails we had seen that Optibiotix (OPTI) had yesterday appointed Luis Gosalbez as Director of Business Development, effective immediately. we are sure that Luis is a charming chappie and his CV looks awesome but it is not even a board appointment so its no great fuss. However....
Good news. This is the sort of thing investors have been wanting Optibiotix (OPTI) to announce and it is delivering. The company says that the trial launch of its Slimbiome® ingredients in a range of meal replacement shakes and natural snack bars went well. In independent tests the ingredients of bars and drinks including Slimbiome showed fatties cutting calorie intakes by 20% or more and suffering fewer cravings.
As house broker to Optibiotix (OPTI), Hybridan is paid to be a fan and on that basis you should really take its bullishness for granted. But a note published a few days ago, before today's cracking news, explains the bull case and since we own shed loads of these shares why not give this most excellent report a wider airing. If the target was 106p pre today's good news surely it would be higher now as analyst Derren Nathan ( not a total poltroon) could cut the risk weighting on one product?
This is more good news from Optibiotix (OPTI) but it is not the dramatic news that will see the shares soaring. The company says that it has announced that it has filed a new patent to protect the combination of OptiBiotix's Lactobacillus plantarum strain along with other ingredients identified by scientific key opinion leaders which, it states, act synergistically to reduce cardiovascular risk factors.
Optibiotix (OPTI) has this week served up news which should help make we shareholders richer in the medium term. But it is NOT the news punters wanted and the shares trade at 79p-80p.
Following Sunday's exclusive news here about an Optibiotix product to help us lose weight being trialled out on Amazon I am asked if that means that the deal with Slimfast, the multi billion dollar slimming drinks company is off? No. It is not. I emailed CEO Steve O'Hara who said:
Certain folks have noticed that a product range called Slimbione has gone on sale and asked if it is anything to do with Optibiotix (OPTI). Here is what CEO Steve O'Hara told us exclusively:
Shares in Optibiotix (OPTI) have drifted on a lack of newsflow back to 76p to buy. Well they had when this article came out yesterday. After its appearance they jumped to 79-92p. That is the advantage paying subscribers get. If you can buy at up to 80p next week do so. We really do see 100p+ happening very soon. Why: we have just swapped emails with the company and what CEO Stephen O'Hara says in response to the question "all a bit quiet is all on track?" seems very positive indeed. O' Hara says:
OptiBiotix Health (OPTI) has announced that it has filed a new patent to protect advances made in its skin division in identifying microbial proteins which have the potential to prevent Health Care Acquired Infections (HCAI) caused by antimicrobial resistant (AMR) superbugs such as MRSA. The company says HCAIs lead to higher morbidity and mortality, and cost the NHS an estimated £1 billion per year. This represents a global market opportunity of $82 billion.
At UK Investor Show on five occasions CEOs appeared on the main stage to pitch to the Dragons (myself, Gary Newman, Steve Moore and Brian Kinane). We invested £15,000 after all these sessions. Enjoy session 5.
In this session Adam Reynolds and I discussed how to value shells and when to invest, issues of management, AIM investment companies and of course Optibiotix (OPTI), New World Oil & Gas (NEW), Frontier (FRI), and Premaitha (NIPT). Enjoy.
We bought this stock and tipped it at 8p. The shares are now c80p and we still hold more than half our holding and won't be selling them for anything less than 100p. we are bullish and after this presentation by Optibiotix (OPTI) boss Steve O'Hara I hope you can see why. Enjoy.
Optibiotix (OPTI) will be presenting on both the main stage and in a breakout room at UK Investor today!. The mood in the camp is incredibly upbeat and we hope you grab a chance to chat to CEO O'Hara to see why.
We own the shares so we are totally biased and a reader who owns the shares is also biased too but asked us to get our mitts on a recent report from Galvan on Optibiotix (OPTI) and publish it. So here you are.
Hybridan is house broker to Optibiotix (OPTI) and so although I agree with its conclusion this note is clearly biased and feel free to ignore it completely. As for Hybridan, like most brokers. its employees should be strung up with piano wire. But for what it is worth.
A bloke in the City said that although results from Optibiotix's (OPTI) trials of its capsular supplement to reduce cholesterol looked great he was so fat that he was beyond redemption. Maybe. But for others results were startling. There is a caveat:
Shares in Optibiotix (OPTI) slipped back to 66.5p - albeit in thin volumes - two days ago as it announced news which was really not very exciting at all. The news we want we now expect very shortly after Easter. The shares are now 70p. Hang on for what comes next!
Optibiotix (OPTI) shares trade at 69p-70p having slipped on news yesterday which was "the wrong sort of good news". Fear not. The right sort is imminent. The wrong good news was that it has set up a 52% owned JV with the University of Manchester called SkinBiotix. Optibiotix says that:
We own stacks of shares in Optibiotix (OPTI) so naturally we agree with Hybridan analyst Derren Nathan that the shares are cheap at 71p. Mr Nathan published a new note late last week so you can make up your own mind. We expect big news soon and sure are not selling our shares.
Broker Hybridan has not (yet) published research on Optibiotix (OPTI) following last week's City presentation. But it has sent a private email to certain clients and, put it this way, we are not going to be selling on the basis of what follows. It strikes me that we may see some very big news soon. Hybridan director of Corporate Broking William Lynne states his key takeaways:
Optibiotix (OPTI) yesterday announced that it had raised £1 million at 78p. It saw this as a triumph in that the investor is an EIS fund which approached it. So the shares will be held for three years and not flipped.
Optibiotix (OPTI) last week announced a potentially massive deal with Slimfast. But no-one seems to have noticed as the deal anounced is with KSF Acquisition Ltd. Investors appear to be saying KSF who?
Featuring shares in Berkeley Energia (BKY), Glenwick (GWIK), MX Oil (MXO), Obtala Resources (OBT), Optibiotix (OPTI) and Rare Earth Minerals (REM) with share price targets for all six stocks.
We own these shares so feel free to ignore what we say. But for the avoidance of doubt our next top slice order is with our broker at more than 95.4p. In fact it is at more than 100p. Hybridan is house broker to Optibiotix (OPTI) so its research cannot be regarded as impartial either. It is paid by Optibiotix. But it has just published a note with a big upgrade so here you are.
Featuring shares in Castle Street Investments (CSI), Mobile Streams (MOB), Optibiotix (OPTI), Pantheon Resources (PANR) and Tern (TERN) with share price targets set for all five stocks.
Featuring shares of Independent Resources (IRG), Optibiotix (OPTI), Oxus Gold (OXS), Stratex (STI), Vast Resources (VAST), together with some share price targets.
Featuring shares in Aminex (AEX), Audioboom (BOOM, Concha (CHA), Optibiotix (OPTI), Sovereign Mines of Africa (SMA), together with some share price targets.
We own shed load of these shares and would certainly not be selling at the current 49.5p bid as we expect big news soon and so I offer no comment on this note from house broker Hybridian on Optibiotix (OPTI) out last week. So Just FYI
OptiBiotix Health (OPTI) has announced the registration of five new microbial strains under the Budapest Treaty, increasing the number of registrations to eight, to protect the “recent advances” the company notes to have made.
Optiobiotix (OPTI) last weekreleased the much awaited results of the human trials. Or rather it has not. Mr Market has not twigged this at all. The shares are a buy at 42p or below as we expect them to be heading towards 60p VERY quickly.
I’m biased as RMPC owns stacks of these shares. So please take that caveat on board but here is a pretty comprehensive note on Optibiotix (OPTI) from Investor’s Champion which – I think – explains why you should be so excited about this stock.
It is all very well to ridicule the Daily Telegraph’s top ten AIM shares to buy to dodge IHT as I did yesterday HERE but could you do any better asks a reader. Possibly not, I don’t really like the AIM Casino but I am always up for a challenge so here goes.
If you want me to analyse a stock for you just drop me a line at email@example.com - Today I look at shares of Argos Resources (ARG), Optibiotix (OPTI), Zoo Digital (ZOO) and offer some share price targets.
The numbers for the six months to May 31 from Optibiotix (OPTI), the AIM listed developer of compounds to tackle obesity, high cholesterol and diabetes matter far less than the supporting text. If you can buy at 40.5p or below (the spread is now 39-40.5p) do so as we see a September whoosh for the shares.
Featuring shares in AMC Minerals (AMC), Falkland Oil & Gas (FOG), Gulf Keystone (GKP), Optibiotix (OPTI), Rockhopper Exploration (RKH), Xtract Resources (XTR) with share price targets for all
OptiBiotix Health (OPTI) has announced completion of clinical studies on its capsular food supplement to reduce cholesterol with no compliance or safety concerns raised. This is good news.
Last time we tipped these shares we made 200% plus. So far this time we are a shade down. But that presents a new buying opportunity created by general market weakness.
AIM listed Optibiotix (OPTI) has been a massive winner for us as a share tip already on HotStockRockets - we banked a 200% + gain back in March the first time we tipped the shares and we tipped them at 39p a month ago. Right now they are up a smidgeon% but we expect a big move very shortly... Let us explain
Hybridan is house broker to Optibiotix (OPTI) and so its views can be largely ignored.It is paid to be bullish. But by way of background here is its post results commentary which we happen to agree with. Busted clocks and all of that.
We have tipped Optibiotix (OPTI) before and our readers have banked big gains on it. Now the time is right for re-entry and this Adam Reynolds biotech play is one of our two tips of the month - the other can be found HERE for just a fiver. As ever, no member of our team will sell until 24 hours after a sell note has gone out on HotStockRockets.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at Camkids, China Chaintek, Optibiotix
If you want me to analyse a stock for you just drop me a line at email@example.com - I start this daily feature with a look at Optibiotix (OPTI) , Plethora (PLE) and Tungsten (TUNG).
I am asked by a couple of readers whether RMPC is buying more Optibiotix (OPTI) or selling as the shares have fallen back to 31p from c40p. As we do not follow this as an official tip I just pen a couple of thoughts.
Adam Reynolds is the shellmeister, the company rescurer (see HERE) and he gave a masterclass presentation at the UK Investor Show on how to make money from shells and how they work. Enjoy
The largest holding that Real Man has in its portfolio is Optibiotix (OPTI). At 34.5p we are, quite amazingly, looking at a 300% profit (plus warrants) on our initial investment. The size of the holding is, I admit, a trifle frightening as are the gains. But although we have advised readers to bank gains we are not doing that ourselves. Are we mad? I think not.
OptiBiotix Health (OPTI) has announced the appointment of a Commercial Director – Jim Laird – who has worked in commercial and corporate roles for some of the world's leading food companies and should enable OptiBiotix to develop a wider range of product and partnering opportunities.
Lets be upfront, RMPC owns this shares and since I often say that all brokers notes are worthless piffle I cannot make an exception here. However broker Hybridan has initiated its coverage of Optibiotix (OPTI) with a very bullish assessment indeed.
We told you on Wednesday that hot news was on the way. On Thursday OptiBiotix (OPTI) announced that it had agreed a 50/50 jv deal with Nizo – the Dutch company that tested its products in yoghurts and found them safe non taste altering.
Last week Optibiotix (OPTI) announced that it had appointed three men in white coats to its Scientific Advisory board. We are sure that Professor Patrice D Cani, Professor Jens Walter and Steven Morrison are all good chaps but it is not the sort of news that tends to get investors that excited.
As I noted in my ten macro themes for 2015 article (HERE) the analysis that Steve Moore and I serve up is bottom up – that is to say company specific – not so much macro driven. But the odd macro think session establishes useful tramlines for the investment process. My first, second and third share tips for 2015 are already live and so onto Number 4.
Shares in Optibiotix (OPTI) are now trading at 22p -22.5p – it was only a few months ago that we tipped them at a 9p offer. There is news today but the fun is only just beginning. The announcement today is not exactly concrete but shows momentum. It reads:
I tipped Optibiotix (OPTI) at 10p just three weeks ago and the shares are now 21p. Normally I’d say sell the lot and thanks for a 110% gain but on this occasion…
We tipped shares in Optiobiotix (LSE:OPTI) just a few months ago at a 9p offer. Knock me down with a feather they closed Friday at 20.75p-21.25p. But the fun is not over yet. We urged you strongly a week ago to buy at up to our limit buy price of 15p as the last chance to get in cheap. We hope that advice was taken even if you ignored the original tip.
OptiBiotix Health (OPTI) has announced positive results of trials of its anti-obesity compounds in fruit yoghurts in tests carried out by its Dutch partner Nizo. The trials showed clearly that adding the compounds did not impact on taste, texture, etc.
Today I start a collection of three biotech companies that I think have brilliant upside potential. Biotech firms can fly on bullish news on their products and these are three firms that I am banking on to do that. These could be genuine multibaggers if they meet expectations or grind lower if they do not.
Heck, I am biased, we own these shares, but I thought that the presentation by Steve O'Hara and Adam Reynolds of Optiobiotix (OPTI) at the second ShareProphets seminar was pretty compelling. I certainly view the shares as cheap on the basis of what I heard. To ensure that you get priority booking for future seminars (the next one is on 27 October ) and features myself, Amanda van Dyke of Bluebird Merchant Ventures, Rob Proctor of Audioboo and Cathal Friel of Fastnet Oil & Gas register HERE.
OptiBiotix Health (OPTI), the former Ducat Ventures, has announced it is contracting Netherlands-based Nizo Food Research BV to undertake pre-clinical claims support for three cholesterol-lowering ‘Lactobacillus’ strains that OptiBiotix has developed.
I am feeling rather virtuous today. Just a Greek salad and a coke to eat and I have already done one hour’s manual labour in the fields. I am just off for another stint now. I am pretty sure that my Body Mass Index is back in the “normal” range and as someone with diabetes – thanks to eating and drinking too much – that is good news. I’m heading the right way. But the rest of the world is not.